Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended September 30, 2016, filed on October 31, 2016. The company is an Australian biotechnology entity subject to ASX Listing Rule 4.7B, focusing on research and development activities.
Key Financial Metrics
| Metric | Value (AUD '000) |
|---|---|
| Cash and Cash Equivalents (End of Quarter) | 25,409 |
| Net Cash Used in Operating Activities | (2,497) |
| Net Cash Used in Investing Activities | (4) |
| Net Cash from Financing Activities | 0 |
| Receipts from Customers | 0 |
| Interest Received | 48 |
| Payments for R&D | (1,562) |
| Staff Costs | (646) |
| Administration and Corporate Costs | (317) |
| Advertising and Marketing | (20) |
| Debt / Borrowings | 0 |
Note: The filing does not provide revenue, profit, or margin figures as the company is in a pre-revenue R&D phase.
Material Changes and Liquidity
- Cash Position: Cash and cash equivalents decreased from $28,594,000 at the beginning of the quarter to $25,409,000 at the end, a net decrease of $3,185,000.
- Operating Burn: The primary driver of cash reduction was operating activities, consuming $2,497,000, primarily due to R&D expenditures ($1,562,000) and staff costs ($646,000).
- Exchange Rate Impact: A movement in exchange rates reduced cash holdings by $684,000.
- Subsequent Event: Following the quarter end, the company received a $4.8 million R&D Tax Incentive cash refund.
Outlook and Management Commentary
- Estimated Cash Outflows: Management estimates total cash outflows for the next quarter to be $5,081,000. This includes $3,476,000 for R&D, $678,000 for staff costs, and $907,000 for administration.
- Financing Facilities: The company currently has no drawn loan facilities or credit standby arrangements.
- Related Party Payments: Payments to directors and associates totaled $258,000 for the quarter, covering salaries, fees, and consulting at commercial rates.
Investor Verification Checklist
- Verify the impact of the $4.8 million R&D Tax Incentive refund received post-quarter on current liquidity.
- Confirm the sufficiency of the $25.4 million cash balance against the projected $5.1 million quarterly burn rate.
- Monitor the company's zero revenue status and continued reliance on cash reserves for R&D.
- Review the exchange rate sensitivity given the $684,000 reduction in cash due to currency movements.